Business Context and Reporting Period
This Form 8-K is filed by Xenomics, Inc. (not Cardiff Oncology, Inc., as noted in the metadata request) on April 11, 2008. The report details the entry into a material definitive agreement: Amendment No. 4 to a Warrant and Put Option Agreement with Gian Luigi Longinotti-Buitoni, the Executive Chairman and Lead Investor.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or margin data. The specific financial terms disclosed relate to a potential capital raise:
- Maximum Put Amount: Up to $1,500,000.
- Purchase Price: $0.55 per share of common stock.
- Additional Shares Option: The Lead Investor retains the option to purchase an additional 2,727,272 shares at $0.70 per share or an additional $1,900,000 under attached warrants.
- Debt and Liquidity: No specific debt or liquidity figures are provided in this text.
Material Changes
The primary change is the extension of the deadline for the Company to exercise a put option. Previously, the Financing Condition had not been met. Under this amendment:
- The deadline for the Company to notify the Lead Investor of the exercise of the Put Option is extended to May 15, 2008.
- If notified by this date, the Lead Investor must purchase the specified Units by May 16, 2008.
- Existing warrants held by the Lead Investor are terminated, except for those underlying the Maximum Put Option and the Additional Shares.
Guidance, Outlook, and Risks
Management Commentary: The amendment was approved by disinterested members of the Board of Directors to preserve the Company's right to secure funding despite the failure to meet the original Financing Condition.
Risks and Contingencies: The Company's ability to raise the $1,500,000 is contingent upon the Company's sole discretion to exercise the put option by May 15, 2008. If the Company does not exercise this option by the deadline, the opportunity to compel the Lead Investor to purchase these specific units expires.
Investor Verification Checklist
- Verify the current cash position of Xenomics, Inc. to assess the necessity of exercising the put option.
- Confirm the exact number of shares outstanding to calculate potential dilution if the $1,500,000 put option is exercised at $0.55 per share.
- Review the status of the "Financing Condition" mentioned in the agreement to understand why the original terms were not met.
- Check for any subsequent filings indicating whether the put option was exercised by the May 15, 2008 deadline.